Discuss How Immunological Tolerance Be Achieved Clinically with UCB | Immunogenicity, 29th - 30th June 2015, London, UK

Share Article

Following on from the success of the inaugural Immunogenicity conference last year, SMi announces their 2nd annual Immunogenicity conference on the 29th & 30th June 2015 in London, UK.

News Image
Explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays

With the increase in demand for biologics in the Pharmaceutical Industry its important medicines are assessed for immunogenicity and methods to induce tolerance. Against this backdrop, SMi’s 2nd annual Immunogenicity conference will explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays. Through a series of interactive presentations, selected case studies from leading drug development teams, bioanalytical experts, and academics, this year’s programme will provide insight on developments necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.

Renowned industry expert Farnaz Fallah-Arani, Chief Scientific Officer and Founder from UCB will be speaking on day 1, her presentation will discuss how immunological tolerance be achieved clinically; the pro’s and con’s of in vitro and in vivo assays of modelling immunological tolerance pre-clinically and how well do these pre-clinical models translate into the clinic.

Expert speaker panel for 2015 includes: Annie De Groot, CEO and CSO, EpiVax, Inc., Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta’s Hospital, Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum, Morten Nielsen, Associate Professor, The Technical University of Denmark, Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg, Chloé Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University of Brussels and many more.

In addition to the event, there will be an interactive workshop taking place on the 1st July entitled: Tools for early immunogenicity risk assessment and reduction, hosted by Sofie Pattijn, CTO, ImmunXperts SA and Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark

This workshop will give an overview of in silico and in vitro tools and technologies to assess and reduce immunogenicity at an early development stage. Next to the technical details and case studies, there will also be an overview of the benefits and limitations of the different tools and how to implement these into your drug development strategy.

A brochure with a full list of speakers and presentations is available to download online. For further information or to book a place, visit Marriott Regents Park Hotel, London, UK
http://www.immuno.co.uk/prweb

Delegate enquiries: Contact Frederick Agboletey on +44 (0)20 7827 6070 or email: fagboletey(at)smi-online(dot)co(dot)uk

Immunogenicity is proudly sponsored by: SQI Diagnostics

2nd Annual Immunogenicity conference
29th & 30th June 2015
Marriott Regents Park Hotel, London, UK
http://www.immuno.co.uk/prweb

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Teri Arri
SMi Group Ltd
+44 207 827 6162
Email >
@Pareapp
Follow >
Pareapp

Visit website